Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 31 min 59 sec ago

Cardio3 BioSciences Announces the Nomination of Three Co-principal Investigators for its CHART-2 Phase III Clinical Trial of C-Cure(R) for the Treatment of Heart Failure

Wed, 11/26/2014 - 14:14
Dr Bernard J. Gersh, Dr Thomas Povsic and Dr Gerasimos Filippatos will be Co-Principal Investigators of the phase III clinical trial CHART-2, authorized by the FDA in January CHART-2 is expected to start by the end of 2014 MONT-SAINT-GUIBERT, Belgium...
Regenerative Medicine, Cardiology
Cardio3 BioSciences, CHART-2 study, C-Cure, stem cell

Eleven Biotherapeutics Announces Additional Financing of $20 Million

Tue, 11/25/2014 - 15:37
Proceeds to Supplement Development of Potential Treatments of Moderate to Severe Dry Eye Disease, Moderate to Severe Allergic Conjunctivitis and Diabetic Macular Edema CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Eleven Biotherapeutics (EBI...
Biopharmaceuticals, Ophthalmology, Venture Capital
Eleven Biotherapeutics, Conjunctivitis, Diabetic Macular Edema

Vascular Solutions Receives 510(k) Clearance for Gel-Block(TM) 10x Embolization Product

Tue, 11/25/2014 - 15:34
Catheter-delivered gelatin pledgets targeting treatment of hypervascular tumors and arteriovenous malformations (AVMs) available for immediate U.S. launch Pre-formed, ready-to-deliver pledgets eliminate the need for physicians to cut and manufacture the...
Devices, Interventional, FDA
Vascular Solutions, Gel-Block, embolization, arteriovenous malformation

Valeant Pharmaceuticals Announces FDA Approval Of ONEXTON(TM) Gel For The Treatment Of Acne Vulgaris

Tue, 11/25/2014 - 15:30
LAVAL, Quebec , Nov. 25, 2014 (Healthcare Sales & Marketing Network) -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that it has received approval from the Food and Drug Administration (FDA) for ONEXTON™ Gel (clind...
Biopharmaceuticals, Dermatology, FDA
Valeant Pharmaceuticals, ONEXTON, clindamycin, acne vulgaris

Implanet Stands out at the North American Spine Society (NASS) Annual Meeting and Signs Six New Distribution Agreements

Mon, 11/24/2014 - 16:18
BORDEAUX, France & BOSTON--(Healthcare Sales & Marketing Network)--IMPLANET (IMPL.PA) (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, reports that its JAZZ implant was the ...
Devices, Orthopaedic, Neurosurgery, Distribution
Implanet, JAZZ implant, spine surgery

Bioniche Life Sciences Inc. Rebrands as Telesta Therapeutics Inc.

Mon, 11/24/2014 - 16:13
BELLEVILLE, ON , Nov. 24, 2014 (Healthcare Sales & Marketing Network) - Bioniche Life Sciences Inc. (TSX: BNC PNK: BNHLF) Bioniche Life Sciences today announced the accomplishment of another major milestone in the execution of its strategic plan to beco...
Bioniche Life Sciences, Telesta Therapeutics

Agilis Biotherapeutics Names Former Shire Executive Dr. Gregory Robinson as Chief Scientific Officer

Mon, 11/24/2014 - 16:10
CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Agilis Biotherapeutics, LLC, a synthetic biology-based company focused on developing DNA-based therapeutics for rare genetic diseases, announced today that Greg Robinson, Ph.D., has been named Chief...
Biopharmaceuticals, Personnel
Agilis Biotherapeutics

Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices

Fri, 11/21/2014 - 13:34
DUBLIN, Ohio and MELVILLE, N.Y., Nov. 21, 2014 -- (Healthcare Sales & Marketing Network) -- Cardinal Health, Inc. (CAH), one of the world's largest health care services companies, and Henry Schein, Inc. (HSIC), the world's largest provider of health care ...
Biopharmaceuticals, Devices, Distribution
Henry Schein, Cardinal Health

Breckenridge Announces Appointment of New President

Thu, 11/20/2014 - 17:53
BOCA RATON, Fla., Nov. 20, 2014 -- (Healthcare Sales & Marketing Network) -- Breckenridge Pharmaceutical, Inc. announced the appointment of Larry Lapila to the position of President. Lapila previously served as Executive Vice President and has been with t...
Biopharmaceuticals, Personnel
Breckenridge Pharmaceutical

Jade Therapeutics Names Ophthalmology Pioneer Randall Olson, M.D., to its Board of Directors

Thu, 11/20/2014 - 16:28
Leading force behind the John A. Moran Eye Center SALT LAKE CITY, Nov. 20, 2014 -- (Healthcare Sales & Marketing Network) -- Jade Therapeutics, Inc., announced today the election of Randall Olson, M.D., Chief Executive Officer and Chair of the Departme...
Biopharmaceuticals, Ophthalmology, Drug Delivery, Personnel
Jade Therapeutics

Crescendo Bioscience Highlights New Clinical Data on Vectra(R) DA at ACR

Wed, 11/19/2014 - 13:42
Data Show Vectra DA is Better Predictor of Joint Damage in RA Patients SALT LAKE CITY, Nov. 19, 2014 -- (Healthcare Sales & Marketing Network) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (MYGN), today presented new data t...
Myriad Genetics, Crescendo Bioscience, Vectra DA, rheumatoid arthritis

Argon Medical's CLEANER XT(TM) and CLEANER 15(TM) Rotational Thrombectomy Systems Receive FDA Clearance for Mechanical Declotting and Infusion in the Peripheral Vasculature

Wed, 11/19/2014 - 13:35
PLANO, Texas, Nov. 19, 2014 -- (Healthcare Sales & Marketing Network) -- Argon Medical Devices, Inc. announced today that the company has received clearance from the US Food and Drug Administration to begin marketing the CLEANER XT™ and CLEANER 15™ Rotati...
Devices, Interventional, FDA
Argon Medical Devices, CLEANER XT, CLEANER 15, Thrombectomy

Cordis Corporation Leads With Strong Podium Presence At VEITH 2014 With First-Ever Presentation Of Three-Year INCRAFT(R) System Data

Wed, 11/19/2014 - 13:28
FREMONT, Calif., Nov. 19, 2014 -- (Healthcare Sales & Marketing Network) -- Cordis Corporation announced today the presentation of new data from the most recent clinical studies at the 2014 VEITHsymposium®, showcasing the company's diverse and strong ...
Devices, Interventional
Cordis , Johnson & Johnson, INCRAFT System, AAA, stent graft

AdvanDx Receives FDA 510(k) Clearance for mecA XpressFISH(TM)

Tue, 11/18/2014 - 19:20
Unique Phenotypic Targeting Approach Provides Physicians with a Better, Faster Way to Identify MRSA and MSSA mecA XpressFISH Gives Blood Culture Results in Approximately One Hour Versus 48-72 Hours WOBURN, Mass., Nov. 18, 2014 -- (Healthcare Sales & Ma...
Diagnostics, FDA
AdvanDx, mecA XpressFISH, MRSA, MSSA

Intellia Therapeutics Announces $15 Million in Funding to Develop Therapeutic Products Utilizing CRISPR-Cas9 Gene Editing Technology

Tue, 11/18/2014 - 19:04
Scientific Pioneers, Industry Veterans Advance Company toward IND Filing CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Intellia Therapeutics, a new company formed to develop therapeutic products using CRISPR-Cas9 technology for gene editing ...
Biopharmaceuticals, Venture Capital
Intellia Therapeutics, CRISPR-Cas9

Antares Pharma Appoints James E. Fickenscher, Senior Vice President, Chief Financial Officer

Tue, 11/18/2014 - 19:00
EWING, N.J.--(Healthcare Sales & Marketing Network)--Antares Pharma, Inc. (ATRS) today announced the appointment of James E. Fickenscher to the position of Senior Vice President, Chief Financial Officer. Mr. Fickenscher has a diversified corporate backgrou...
Biopharmaceuticals, Personnel
Antares Pharma

First U.S. Procedures Completed With The Symphion(TM) Hysteroscopic Tissue Removal System

Mon, 11/17/2014 - 16:38
MARLBOROUGH, Mass., Nov. 17, 2014 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (BSX) announces the completion of the first U.S. procedures performed with the Symphion System, designed for the hysteroscopic removal of interute...
Devices, Product Launch
Boston Scientific, Symphion, hysteroscope, hysteroscopic

Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer

Mon, 11/17/2014 - 16:09
DUBLIN, Nov. 17, 2014 -- (Healthcare Sales & Marketing Network) -- Actavis plc (ACT) today announced that it has successfully completed its tender offer to purchase all outstanding shares of Durata Therapeutics, Inc. (DRTX), an innovative pharmaceutical c...
Biopharmaceuticals, Mergers & Acquisitions
Actavis, Durata Therapeutics, DALVANCE, antibiotic

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong